Physician profile
Mario Cauli
NPI 1043273568
$27,164.57
in general payments reported to CMS, 2019-2025
59 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,436 · 2020: $2,252 · 2021: $4,033 · 2022: $10K · 2023: $5,379 · 2024: $2,916 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,911 · Consulting Fee: $463 · Education: $36.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,910.65 |
| Consulting Fee | $463.00 |
| Education | $36.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $5,933.94 | 2022-2023 | Trudhesa |
| Biogen, INC. | $1,867.00 | 2019-2025 | Vumerity, Tysabri |
| Sk Life Science, INC. | $1,614.90 | 2020-2024 | Xcopri |
| Emd Serono, INC. | $1,532.43 | 2019-2024 | Mavenclad |
| Ucb, INC. | $1,016.44 | 2019-2024 | Briviact, Nayzilam |
| Neurocrine Biosciences, INC. | $978.07 | 2020-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $962.07 | 2019-2024 | Qulipta, Ubrelvy, Duopa |
| Novartis Pharmaceuticals Corporation | $886.59 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $823.40 | 2019-2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $804.18 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Genzyme Corporation | $788.75 | 2019-2023 | |
| Mdd US Operations, LLC | $785.17 | 2022-2025 | Gocovri, Apokyn, Myobloc |
| Amgen INC. | $765.00 | 2019-2023 | Aimovig |
| Csl Behring | $756.72 | 2019-2024 | Hizentra |
| Sunovion Pharmaceuticals INC. | $666.68 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Cauli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.